The Administrative Core, directed by Dr. Hagop Kantarjian, provides critical centralized administrative support to ensure the success of the entire SPORE. The specific objectives of the Administrative Core are: Oversee all SPORE activities, in particular the research activities Promote integration and communication between the SPORE, the Leukemia Program, and the Cancer Center Support (Core) Grant Ensure compliance with institutional, governmental, and NCI regulations Assume responsibility for coinmunications and consultations with the NCI project officer and other NCI staff to ensure timely preparation and submission of reports and publications Oversee the fiscal and budgetary activities of the SPORE Coordinate data control quality assurance issues in conjunction with the Internal Scientific Advisory Committee and the Biostatistics and Data Management Core (Core C) Coordinate activities associated with clinical trials, e.g., designs, approval by regulatory bodies, implementation, and eligibility and assignment of patients to different studies Provide oversight and support for the Biostatistics and Data Management Core (Core C) and the Pathology and Tissue Core (Core B) Coordinate meetings of the [Executive Committee, the Internal and External Scientific Advisory Committees, monthly investigator meetings, quarterly research meetings, lectures, and symposia Administer the Developmental Research Program and the Career Development Program Administer the activities of the Patient Advocates Ensure compliance with and improvement of policies for recruitment of women and minorities Coordinate with other Leukemia SPORE programs and investigators, and other organ-site SPORE programs, to promote communications and integration, through sponsoring a yearly SPORE conference, and distribute materials, electronic communications and progress reports Organize seminars to bring to M. D. Anderson consultants and speakers;sponsor a yearly conference on Translational Research in Leukemia

Public Health Relevance

(See InstrLctions): The Administrative Core provides the support and infrastructure for research and financial oversight;clear and open communications among all SPORE investigators, patient advocates, and developmental awardees;and regulatory monitoring to optimize the successful outcome of the translational research in leukemia.

National Institute of Health (NIH)
National Cancer Institute (NCI)
Specialized Center (P50)
Project #
Application #
Study Section
Special Emphasis Panel (ZCA1)
Project Start
Project End
Budget Start
Budget End
Support Year
Fiscal Year
Total Cost
Indirect Cost
United States
Zip Code
St John, Lisa S; Wan, Liping; He, Hong et al. (2016) PR1-specific cytotoxic T lymphocytes are relatively frequent in umbilical cord blood and can be effectively expanded to target myeloid leukemia. Cytotherapy 18:995-1001
Lee, H J; Gallardo, M; Ma, H et al. (2016) p53-independent ibrutinib responses in an Eμ-TCL1 mouse model demonstrates efficacy in high-risk CLL. Blood Cancer J 6:e434
Pemmaraju, Naveen; Kantarjian, Hagop; Ravandi, Farhad et al. (2016) Patient Characteristics and Outcomes in Adolescents and Young Adults (AYA) With Acute Myeloid Leukemia (AML). Clin Lymphoma Myeloma Leuk 16:213-222.e2
Van Roosbroeck, Katrien; Fanini, Francesca; Setoyama, Tetsuro et al. (2016) Combining anti-miR-155 with chemotherapy for the treatment of lung cancers. Clin Cancer Res :
Ravandi, Farhad; Jorgensen, Jeffrey L; O'Brien, Susan M et al. (2016) Minimal residual disease assessed by multi-parameter flow cytometry is highly prognostic in adult patients with acute lymphoblastic leukaemia. Br J Haematol 172:392-400
Chawla, Akhil; Alatrash, Gheath; Philips, Anne V et al. (2016) Neutrophil elastase enhances antigen presentation by upregulating human leukocyte antigen class I expression on tumor cells. Cancer Immunol Immunother 65:741-51
Wen, Sijin; Huang, Xuelin; Frankowski, Ralph F et al. (2016) A Bayesian multivariate joint frailty model for disease recurrences and survival. Stat Med 35:4794-4812
Kanagal-Shamanna, Rashmi; Luthra, Rajyalakshmi; Yin, Cameron C et al. (2016) Myeloid neoplasms with isolated isochromosome 17q demonstrate a high frequency of mutations in SETBP1, SRSF2, ASXL1 and NRAS. Oncotarget 7:14251-8
Pan, D; Jiang, C; Ma, Z et al. (2016) MALT1 is required for EGFR-induced NF-κB activation and contributes to EGFR-driven lung cancer progression. Oncogene 35:919-28
Saenz, D T; Fiskus, W; Manshouri, T et al. (2016) BET protein bromodomain inhibitor-based combinations are highly active against post-myeloproliferative neoplasm secondary AML cells. Leukemia :

Showing the most recent 10 out of 377 publications